TELA Stock Analysis: Buy, Sell, or Hold?
TELA - TELA Bio, Inc. Common Stock
$0.75
-0.04 (-4.54%)
βΌ
5d:
-16.41%
30d:
-15.73%
90d:
-1.47%
WAIT
LOW Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When TELA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
βΈοΈ WAIT FOR STABILIZATION: TELA is down 16.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
βΈοΈ WAIT FOR STABILIZATION: TELA is down 16.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TELA is currently trading at $0.75, which is considered oversold relative to its 30-day fair value range of $0.82 to $0.92.
Technical Outlook: Technically, TELA is showing sideways momentum. The price is currently testing key support at $0.82. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.25 (+200.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TELA is showing sideways momentum. The price is currently testing key support at $0.82. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.25 (+200.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.82 -
$0.92
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.5%)
- BULLISH: Trading 200.0% below Wall St target ($2.25)
- WARNING: Recommendation downgraded due to -16.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.82 -
$0.92
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.82
Resistance Level
$0.98
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.35
Wall Street Target
$2.25
(+200.0%)
Revenue Growth (YoY)
2.9%
Profit Margin
-49.3%
Share & Embed Analysis
Last updated: June 24, 2026 9:44 PM ET
Data refreshes hourly during market hours. Next update: 10:44 PM
Data refreshes hourly during market hours. Next update: 10:44 PM
π₯ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TELA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$77 | 62 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 67 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 56 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 65 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$242 | 65 BUY |